AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

- 1. (Currently Amended) Tetrapeptide lysyl-glutamyl-aspartyl-tryptophane amide amide of the general formula Lys-Glu-Asp-Trp-NH₂[SEQ ID NO:1].
 - 2. (Canceled).
- 3. (Currently Amended) Pharmaceutical substance A pharmaceutical composition comprising of peptide nature, capable of regulating glucose level; containing an active peptide agent and a pharmaceutically admissible carrier, which is distinguished by the fact that it contains as its active base and an effective quantity of tetrapeptide Lys-Glu-Asp-Trp-NH₂[SEQ ID NO:1].
- 4. (Currently Amended) The substance described in pharmaceutical composition of claim 3, wherein said substance is presented in a form which is suitable for oral administration.
- 5. (Currently Amended) The substance described in pharmaceutical composition of claim 3, wherein said substance is presented in a form which is suitable for parenteral administration.
- 6. (Currently Amended) The A method of prophylaxis and/or treatment of diabetes mellitus, which consists in administering to the patient of the pharmacological substance, containing as an active peptide agent an effective amount of tetrapeptide Lys-Glu-Asp-Trp-NH₂ [SEQ ID NO:1] tetrapeptide in doses of 0,1-30 μg/kg of the body weight at least once a day for a period necessary for attaining a therapeutic effect.
- 7. (Currently Amended) The method of claim 6 wherein the pharmacological substance is intended for parenteral administration tetrapeptide is administered parenterally.
- 8. (Currently Amended) The method of claim 6 wherein the pharmacological substance is intended for oral administration tetrapeptide is administered orally.

9. (Currently Amended) The method of elaim 7 claim 6 wherein the pharmacological substance described in claims 3-5 is active when tetrapeptide is administered in doses of 0,1-30 0.1-30 mg/kg of the body weight.